{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:45:07Z","timestamp":1768455907742,"version":"3.49.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"ANRS-MIE"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The aim of this study was to evaluate changes in prevalence of resistance to integrase strand transfer inhibitors (INSTIs) in relation to changes in their use over 16\u2005years in people living with HIV (PLWHIV) treated with antiretrovirals (ARVs) and in virological failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We analysed the use of different INSTIs (for \u22653\u2005months during the study year) in ARV-treated PLWHIV in an academic centre and the HIV INSTI resistance profiles in RNA in case of virological failure (2008\u201324; analysed using the ANRS-MIE algorithm v33).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During the studied period (2008\u201324), INSTI use increased from 3.3% to 71.2%. Raltegravir use peaked at 21.5% in 2013 and then declined to 2.5% in 2024. Elvitegravir followed a similar trend, increasing to 15.7% in 2018 and then decreasing to 1.5% in 2024. Dolutegravir increased steadily from 6.3% in 2014 to 39.3% in 2023 and bictegravir from 2.0% in 2018 to 28.0% in 2024. Cabotegravir, first noted in 2020 (0.3%), will reach 3.8% in 2024. The proportion of patients with INSTI-resistant viruses was initially high for raltegravir (47.8% in 2008), before decreasing. By 2024, resistance was 2.7% for dolutegravir, cabotegravir and bictegravir, but remained higher for raltegravir (8.5%) and elvitegravir (9.8%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although the use of INSTIs has increased over time with differences in the duration of use, we did not observe a corresponding increase in the proportion of ARV-treated PLWHIV who experienced virological failure with INSTI-resistant viruses during the study period.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf454","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T13:17:38Z","timestamp":1764854258000},"source":"Crossref","is-referenced-by-count":0,"title":["Despite increasing use of integrase inhibitors to treat HIV infection, resistance to this class remains stable"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2032-4148","authenticated-orcid":false,"given":"Cathia","family":"Soulie","sequence":"first","affiliation":[{"name":"Laboratoire de virologie, Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re\u2014Charles Foix , 45-83 bd de l\u2019H\u00f4pital, Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachid","family":"Agher","sequence":"additional","affiliation":[{"name":"Service de maladies infectieuses, Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re\u2014Charles Foix , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Fauchois","sequence":"additional","affiliation":[{"name":"Laboratoire de virologie, Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re\u2014Charles Foix , 45-83 bd de l\u2019H\u00f4pital, Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9139-0010","authenticated-orcid":false,"given":"Basma","family":"Abdi","sequence":"additional","affiliation":[{"name":"Laboratoire de virologie, Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re\u2014Charles Foix , 45-83 bd de l\u2019H\u00f4pital, Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3723-4142","authenticated-orcid":false,"given":"Marc","family":"Wirden","sequence":"additional","affiliation":[{"name":"Laboratoire de virologie, Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re\u2014Charles Foix , 45-83 bd de l\u2019H\u00f4pital, Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Teyssou","sequence":"additional","affiliation":[{"name":"Laboratoire de virologie, Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re\u2014Charles Foix , 45-83 bd de l\u2019H\u00f4pital, Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Sayon","sequence":"additional","affiliation":[{"name":"Laboratoire de virologie, Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re\u2014Charles Foix , 45-83 bd de l\u2019H\u00f4pital, Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Katlama","sequence":"additional","affiliation":[{"name":"Service de maladies infectieuses, Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re\u2014Charles Foix , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc-Antoine","family":"Valantin","sequence":"additional","affiliation":[{"name":"Service de maladies infectieuses, Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re\u2014Charles Foix , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Tubiana","sequence":"additional","affiliation":[{"name":"Service de maladies infectieuses, Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re\u2014Charles Foix , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luminita","family":"Schneider","sequence":"additional","affiliation":[{"name":"Service de maladies infectieuses, Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re\u2014Charles Foix , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Faycal","sequence":"additional","affiliation":[{"name":"Service de maladies infectieuses, Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re\u2014Charles Foix , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0047-0101","authenticated-orcid":false,"given":"Romain","family":"Palich","sequence":"additional","affiliation":[{"name":"Service de maladies infectieuses, Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re\u2014Charles Foix , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3879-1480","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Pourcher","sequence":"additional","affiliation":[{"name":"Service de maladies infectieuses, Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re\u2014Charles Foix , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Genevi\u00e8ve","family":"Marcelin","sequence":"additional","affiliation":[{"name":"Laboratoire de virologie, Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re\u2014Charles Foix , 45-83 bd de l\u2019H\u00f4pital, Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Calvez","sequence":"additional","affiliation":[{"name":"Laboratoire de virologie, Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re\u2014Charles Foix , 45-83 bd de l\u2019H\u00f4pital, Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"2026011413280796300_dkaf454-B1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12977-022-00608-1","article-title":"A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection","volume":"19","author":"Zhao","year":"2022","journal-title":"Retrovirology"},{"key":"2026011413280796300_dkaf454-B2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40121-014-0029-7","article-title":"Dolutegravir, the second-generation of integrase strand transfer inhibitors (INSTIs) for the treatment of HIV","volume":"3","author":"Dow","year":"2014","journal-title":"Infect Dis Ther"},{"key":"2026011413280796300_dkaf454-B3","doi-asserted-by":"publisher","first-page":"e067765","DOI":"10.1136\/bmjopen-2022-067765","article-title":"INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial","volume":"12","author":"Naidoo","year":"2022","journal-title":"BMJ Open"},{"key":"2026011413280796300_dkaf454-B4","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/jac\/dkr152","article-title":"Prevalence of resistance mutations related to integrase inhibitor S\/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients","volume":"66","author":"Malet","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2026011413280796300_dkaf454-B5","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1093\/jac\/dkaa042","article-title":"Impact of genotypic diversity on selection of subtype-specific drug resistance profiles during raltegravir-based therapy in individuals infected with B and BF recombinant HIV-1 strains","volume":"75","author":"S\u00e1nchez","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026011413280796300_dkaf454-B6","doi-asserted-by":"publisher","first-page":"e01717-19","DOI":"10.1128\/AAC.01717-19","article-title":"Comparable in vitro activities of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations","volume":"64","author":"Saladini","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413280796300_dkaf454-B7","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1093\/jac\/dkz256","article-title":"A systematic review of the genetic mechanisms of dolutegravir resistance","volume":"74","author":"Rhee","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026011413280796300_dkaf454-B8","doi-asserted-by":"publisher","first-page":"e0164321","DOI":"10.1128\/AAC.01643-21","article-title":"Integrase inhibitor resistance mechanisms and structural characteristics in antiretroviral therapy-experienced, integrase inhibitor-naive adults with HIV-1 infection treated with dolutegravir plus two nucleoside reverse transcriptase inhibitors in the DAWNING study","volume":"66","author":"Underwood","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413280796300_dkaf454-B9","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1093\/jac\/dkad101","article-title":"Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings","volume":"78","author":"Armenia","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026011413280796300_dkaf454-B10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/QAI.0b013e3181eb376b","article-title":"Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV","volume":"55","author":"German","year":"2010","journal-title":"J Acquir Immune Defic Syndr 1999"},{"key":"2026011413280796300_dkaf454-B11","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S1473-3099(11)70196-7","article-title":"Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial","volume":"11","author":"Eron","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"2026011413280796300_dkaf454-B12","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"Raffi","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2026011413280796300_dkaf454-B13","doi-asserted-by":"publisher","first-page":"e46767","DOI":"10.2196\/46767","article-title":"Safety and efficacy of long-acting injectable agents for HIV-1: systematic review and meta-analysis","volume":"9","author":"Wang","year":"2023","journal-title":"JMIR Public Health Surveill"},{"key":"2026011413280796300_dkaf454-B14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12977-018-0440-3","article-title":"Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir","volume":"15","author":"Oliveira","year":"2018","journal-title":"Retrovirology"},{"key":"2026011413280796300_dkaf454-B15","author":"Bello"},{"key":"2026011413280796300_dkaf454-B16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/cid\/ciae261","article-title":"Virologic Failure and Drug Resistance After Programmatic Switching to Dolutegravir-based First-line Antiretroviral Therapy in Malawi and Zambia","volume":"80","author":"Skrivankova","year":"2025","journal-title":"Clin Infect Dis."},{"key":"2026011413280796300_dkaf454-B17","author":"Kingwara"},{"key":"2026011413280796300_dkaf454-B18","author":"Ju\u00e1rez-Gonz\u00e1lez JA, Sanchez Cruz EI, Angulo-Medina LA"},{"key":"2026011413280796300_dkaf454-B19","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1093\/jac\/dkae458","article-title":"Changes in NNRTI use have not altered the ecology of NNRTI resistance over the last 10\u2005years in people with HIV experiencing virological failure on antiretroviral drugs","volume":"80","author":"Soulie","year":"2025","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf454\/65923968\/dkaf454.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf454\/65923968\/dkaf454.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:28:16Z","timestamp":1768415296000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf454\/8381498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf454","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,12,16]]},"article-number":"dkaf454"}}